HIA Sainte Anne — Clinical Trial Site

62 Registered trials

23 Currently recruiting

Organisation

HIA Sainte Anne

Location

Toulon Cedex 9, France

Identifier

ORG-100045575

Address

2 Boulevard Sainte Anne, Bp 600, 83800, France

Departments

#1213: Neurology
#2057: Service Dermatologie et vénéréologie
#40285: Service de dermatologie
1815 :Rhumatologie
1815: Internal Medicine
2308:Service de pneumologie
2406:Service de Pneumologie
40887: Service de Dermatologie
Anesthesiology and intensive care
Department of Oncology-Pneumology
Dermatologie Venereologie
Dermatology
Dermatology Department
gastro enterology
Gastroenterolgy
gastroenterology
Hématologie
hépato gastro enterology
Hepatogastroenterology
Internal Medicine
Maladies Respiratoires
Médecine Interne
medical oncology
n/a
NA
Neurologie
Neurology
Neuroradiologie Interventionnelle
Onco-Hématologie
Oncologie
Oncologie-Hématologie
Oncology - Hematology
Pathologie Respiratoire
Pneumologie
Pneumology
Pneumology department
Respiratory
Respiratory Department
Satellite site Pneumology Department
Service de Dermatologie
Service de médecine interne
Service de Pneumologie
Service pneumologie
URC - HIA SAINTE ANNE

Clinical trials at this site (62)

Search interface

A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab … Ended

2024-513697-22-00 non-small-cell lung cancer 5 2024-11-07
Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended

2022-503160-33-00 Hidradenitis Suppurativa 5 2023-12-15
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Polymyalgia Rheumatica 5 2023-09-13
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501753-36-00 Hidradenitis Suppurativa 5 2023-06-02
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with… Ended

2022-502752-31-00 Non-small cell lung cancer 11 2022-04-29
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir… Ended

2023-506074-12-00 Metastatic Non-Small Cell Lung Cancer 5 2022-03-22
Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca… Ended

2024-513707-14-00 Only patients with oncologic locally advanced or metast 5 2022-01-14
An extension study to learn if Bimekizumab is safe and works as a long-term therapy in adults with moderate to severe hidradenitis suppurati… Ended

2024-511035-10-00 Hidradenitis Suppurativa 5 2021-06-23
ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refr… Ended

2024-516670-29-00 Multiple Myeloma 4 2020-09-15
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended

2024-516201-23-00 Lung Cancer, NSCLC 4 2019-08-26
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended

2023-506543-41-00 Multiple sclerosis (MS) 5 2018-07-25
A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemothe… Ended

2023-504209-35-00 Early-Stage Resectable Non-small cell lung cancer (NSCL 5 2018-04-04
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Biliary tract carcinoma 4